A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Margaret E Gatti-MaysNicholas P TscherniaJulius StraussRavi A MadanFatima H KarzaiMarijo BilusicJason Mark RedmanHoussein Abdul SaterCharalampos S FloudasNicole J ToneyRenee N DonahueCaroline JochemsJennifer L MartéDeneise FrancisSheri McMahonElizabeth LampingLisa M CordesJeffrey SchlomJames L GulleyPublished in: The oncologist (2023)
Biweekly NHS-IL12 was well tolerated in this small phase I study. Additional studies incorporating NHS-IL12 with other immunomodulating agents are underway. (ClinicalTrials.gov Identifier: NCT01417546).
Keyphrases